GenMark Diagnostics, Inc
GNMK
GNMK was delisted on the 21st of April, 2021.
148 hedge funds and large institutions have $1,000M invested in GenMark Diagnostics, Inc in 2020 Q2 according to their latest regulatory filings, with 56 funds opening new positions, 52 increasing their positions, 30 reducing their positions, and 17 closing their positions.
366% more capital invested
Capital invested by funds: $214M → $1,000M (+$785M)
229% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 17
90% more call options, than puts
Call options by funds: $3.33M | Put options by funds: $1.75M
73% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 30
35% more funds holding
Funds holding: 110 → 148 (+38)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$70M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$49.8M |
| 3 |
Renaissance Technologies
New York
|
+$21.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.6M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$13.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$46.2M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$18M |
| 3 |
CCM
Cadian Capital Management
New York
|
-$14.4M |
| 4 |
CC
Casdin Capital
New York
|
-$13.9M |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
-$13.4M |
GNMK Hedge Fund Activity: Q2 2020 in Review
148 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in GenMark Diagnostics, Inc (GNMK) for Q2 2020, worth a combined $1,000M — up 366% from $214M a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new GNMK positions and 17 closed out — a net gain of 39 holders — while 52 added to existing stakes and 30 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $70M. The largest seller was Morgan Stanley, cutting an estimated $46.2M.
- 148 institutional investors held GenMark Diagnostics, Inc (GNMK) as of Q2 2020, up from 110 in Q1 2020.
- Funds reported $1,000M of GenMark Diagnostics, Inc stock for Q2 2020, up 366% quarter-over-quarter.
- 56 funds opened new GenMark Diagnostics, Inc positions in Q2 2020 and 17 closed out, a net change of +39 holders.
- The largest GenMark Diagnostics, Inc buyer in Q2 2020 was Consonance Capital Management, an estimated $70M added.
- The largest GenMark Diagnostics, Inc seller in Q2 2020 was Morgan Stanley, an estimated $46.2M sold.
Based on aggregated 13F filings for Q2 2020.